NASDAQ
8.08USD
-0.04 (-0.49%)
We have scored 6 news catalysts on Corbus Pharmaceuticals Holdings, Inc. (CRBP) over the past 12 months. The biggest single-day move next to one of them came May 26, 2026, when CRBP closed −30.3%: “Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript”. Coverage across the window leans positive (average ticker sentiment +0.35). Most of the impact sits in short squeeze potential and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
149.7M
P/E
—
EPS
—
Beta
2.64
52W range
7.12-20.56
Day range
7.72–8.88
Open
7.93
Prev close
8.12
Volume
8.4M
Avg volume
528.5K
Dividend
0.00
IPO
2014-10-27
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Corbus Pharmaceuticals Holdings, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for CRBP: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
